Stock DOVA DOVA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Dova Pharmaceuticals, Inc.

Equities

DOVA

US25985T1025

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Dova Pharmaceuticals, Inc. -0.07% +269.92%
2019 Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag CI
2019 Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase CI

Business Summary

Dova Pharmaceuticals Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD). The Company’s product candidate, avatrombopag is an orally administered thrombopoietin receptor agonist, or TPO-RA. The Company has completed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with CLD. The Company has not generated any revenue.

Managers

Managers TitleAgeSince
Mahmood Ladha PSD
 President 60 12/19/12
Lee F. Allen CTO
 Chief Tech/Sci/R&D Officer 72 01/17/01
Marc Banjak LAW
 General Counsel - -
Bill L. Nichols SAM
 Sales & Marketing - 15/18/15
Stephen Crane SAM
 Sales & Marketing - -
Caroline Diaz LAW
 General Counsel - -
Russell Schundler SEC
 Corporate Secretary 49 -

Members of the board

Members of the board TitleAgeSince
Henrik Stenqvist BRD
 Director/Board Member 57 12/19/12
Guido Oelkers BRD
 Director/Board Member 59 12/19/12
Per Richard Torbjörn Hallberg BRD
 Director/Board Member 55 12/19/12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 28,821,405 13,851,527 ( 48.06 %) 0 48.06 %

Company contact information

Dova Pharmaceuticals, Inc.

240 Leigh Farm Road Suite 245

27707, Durham

+919-748-5975

http://www.dova.com
address Dova Pharmaceuticals, Inc.(DOVA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DOVA PHARMACEUTICALS, INC. Stock Dova Pharmaceuticals, Inc.
+269.92% 808M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.43% 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+13.05% 107B
BIONTECH SE Stock BioNTech SE
-6.60% 22.22B
ARGENX SE Stock argenx SE
-1.66% 21.28B
GENMAB A/S Stock Genmab A/S
-4.59% 18.8B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.02% 17.51B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 17.17B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.40% 14.14B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.50% 12.2B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DOVA Stock
  4. Company Dova Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW